Skip to content

Evaluation of Fortetropin in Geriatric and Senior Dogs With Reduced Mobility

Kenneth R. Harkin, DVM, DACVIM (SAIM)
Hodes Professor and Head, Section of Medicine, Kansas State University College of Veterinary Medicine

Untitled design - 2022-10-18T140954.060

Length: 26:51  File Format: .mp4
26 minute and 51 second research seminar given by Kenneth R. Harkin, DVM, DACVIM (SAIM), Hodes Professor and Head, Section of Medicine, Kansas State University College of Veterinary Medicine on the evaluation of Fortetropin in geriatric and senior dogs with reduced mobility.

Screen Shot 2022-10-20 at 9.44.45 AM

Complete for Instant Access
Screen Shot 2022-10-18 at 1.52.38 PM

SUMMARY

  • Sarcopenia and Osteoarthritis (OA) negatively impact the mobility and quality of life of dogs.

  • Fortetropin supplementation showed mild, but statistically significant, improvement of the mobility scores for the treatment group at both week 6 (P = 0.03) and week 12 (P = 0.006) compared to the baseline score. No statistical improvement was noted at any time in the placebo group or between the treatment and placebo group.

  • Reducing sarcopenia through Fortetropin supplementation can be a valuable component of a multimodal strategy to treat reduced mobility in geriatric dogs.